Zobrazeno 1 - 10
of 229
pro vyhledávání: '"11"'
Autor:
Junko Murai, Yves Pommier
Publikováno v:
Molecular Cancer Research. 15:IA19-IA19
Poly(ADP-ribose) polymerase inhibitors (PARPIs) kill cancer cells by trapping PARP1 and PARP2. Talazoparib, the most potent PARP inhibitor (PARPI), exhibits remarkable selectivity among the NCI-60 cancer cell lines beyond BRCA inactivation. Our genom
Publikováno v:
Molecular Cancer Research. 3:453-461
Ring finger proteins serve many vital functions within the cell. We have identified RNF11, a novel 154-amino acid ring finger–containing protein, which is elevated in breast cancer. Within its ring finger domain, RNF11 contains an AKT phosphorylati
Publikováno v:
Molecular Cancer Research. 11:651-664
The Src homology phosphotyrosyl phosphatase 2 (SHP2) is a positive effector of receptor tyrosine kinases (RTK) signaling. Furthermore, SHP2 is known to promote cell migration and invasiveness, key steps in cancer metastasis. To date, however, the mec
Publikováno v:
Molecular Cancer Research. 13:86-97
Retinoblastoma is the most common pediatric intraocular neoplasm. While retinoblastoma development requires the inactivation of both alleles of the retinoblastoma tumor suppressor gene (RB1) in the developing retina, additional genomic changes are in
Publikováno v:
Molecular Cancer Research. 6:1114-1123
Epigenetic changes occur frequently in Wilms' tumor (WT), especially loss of imprinting (LOI) of IGF2/H19 at 11p15. Our previous results have identified imprinted transcripts (WT1-AS and AWT1) from the WT1 locus at 11p13 and showed LOI of these in so
Publikováno v:
Molecular Cancer Research. 6:186-193
Mesothelin (MSLN) is a glycoprotein that is overexpressed in various tumors. MSLN is present on the cell surface and is also released into body fluids or culture supernatants from MSLN-positive tumor cells. Despite intensive study of MSLN as a diagno
Publikováno v:
Molecular Cancer Research. 18:194-203
MDM2 is an oncogene and critical negative regulator of tumor suppressor p53. Genotoxic stress causes alternative splicing of MDM2 transcripts, which leads to alterations in p53 activity and contributes to tumorigenesis. MDM2-ALT1 is one of the altern
Autor:
Mulder, Celine, Prust, Nadine, Van Doorn, Sander, Reinecke, Maria, Kuster, Bernhard, Van Bergen En Henegouwen, Paul, Lemeer, Simone, Biomolecular Mass Spectrometry and Proteomics, Sub Biomol.Mass Spectrometry & Proteom., Sub Cell Biology, Celbiologie
Publikováno v:
Molecular Cancer Research, 16(11), 1773. American Association for Cancer Research Inc.
Targeted therapies against oncogenic receptor tyrosine kinases (RTK) show promising results in the clinic. Unfortunately, despite the initial positive response, most patients develop therapeutic resistance. Most research has focused on acquired resis
Autor:
Lorena Lazo de la Vega, Scott A. Tomlins, Arul M. Chinnaiyan, Jonathan B. McHugh, Daniel H. Hovelson, Chia Jen Liu, Frances M. Walocko, Paul W. Harms, Dan R. Robinson, Komal Kunder, Andi K. Cani
Publikováno v:
Molecular Cancer Research. 15:1551-1557
Olfactory neuroblastomas (ONBs), also known as esthesioneuroblastomas, are malignant round-cell tumors that represent up to 5% of sinonasal malignancies. Despite their aggressive course, molecular studies of ONBs have been limited, and targeted thera
Autor:
Katharine Chen, Vy M. Tran, Olle R. Lindberg, Anders Persson, Jane R. Engler, Andrew McKinney, Anna Wade, Joanna J. Phillips
Publikováno v:
Molecular cancer research : MCR, vol 15, iss 11
Glioblastoma (GBM) is the most common primary malignant brain tumor of adults and confers a poor prognosis due, in part, to diffuse invasion of tumor cells. Heparan sulfate (HS) glycosaminoglycans, present on the cell surface and in the extracellular